C
Charles D. Swerdlow
Researcher at Cedars-Sinai Medical Center
Publications - 150
Citations - 5077
Charles D. Swerdlow is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Implantable cardioverter-defibrillator & Defibrillation. The author has an hindex of 38, co-authored 147 publications receiving 4556 citations. Previous affiliations of Charles D. Swerdlow include VCU Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction
Fred Kusumoto,Mark H. Schoenfeld,Bruce L. Wilkoff,Charles I. Berul,Ulrika Birgersdotter-Green,Roger G. Carrillo,Yong Mei Cha,Jude Clancy,Jean Claude Deharo,Kenneth A. Ellenbogen,Derek V. Exner,Ayman A. Hussein,Charles Kennergren,Andrew D. Krahn,Richard T. Lee,Charles J. Love,Ruth A. Madden,Hector Alfredo Mazzetti,Jo Ellyn Carol Moore,Jeffrey Parsonnet,Kristen K. Patton,Marc A. Rozner,Kimberly A. Selzman,Morio Shoda,Komandoor Srivathsan,Neil Strathmore,Charles D. Swerdlow,Christine Tompkins,Oussama M. Wazni +28 more
TL;DR: Fred M. Kusumoto,MD, FHRS, FACC, Chair, Mark H. Schoenfeld, MD, F hrs, F ACC, FAHA, CCDS, Vice-Chair, Bruce L. Wilkoff, MD; Ulrika M. Birgersdotter-Green, MD.
Journal ArticleDOI
Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias.
TL;DR: In this article, the authors concluded that amiodarone is useful in the treatment of refractory tachyarrhythmias but that the rate of efficacy in VT/VF is lower and the incidence of significant toxicity is higher than has been generally appreciated.
Journal ArticleDOI
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing
Bruce L. Wilkoff,Laurent Fauchier,Martin K. Stiles,Carlos A. Morillo,Sana M. Al-Khatib,Jesœs Almendral,Luis Aguinaga,Ronald D. Berger,Alejandro Cuesta,James P. Daubert,Sergio J. Dubner,Kenneth A. Ellenbogen,N.A. Mark Estes,Guilherme Fenelon,Fermin C. Garcia,Maurizio Gasparini,David E. Haines,Jeff S. Healey,Jodie L. Hurtwitz,Roberto Keegan,Christof Kolb,Karl Heinz Kuck,Germanas Marinskis,Martino Martinelli,Mark A. McGuire,Luis G. Molina,Ken Okumura,Alessandro Proclemer,Andrea M. Russo,Jagmeet P. Singh,Charles D. Swerdlow,Wee Siong Teo,William Uribe,Sami Viskin,Chun Chieh Wang,Shu Zhang +35 more
TL;DR: In this paper, the authors systematically describe the >80% (83-100%, mean: 96%) required consensus achieved for each recommendation by official balloting in regard to the programming of bradycardia mode and rate, detection, tachycardia therapy, and intraprocedural testing of defibrillation efficacy.
Journal ArticleDOI
Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator
Charles D. Swerdlow,Charles D. Swerdlow,Peng Sheng Chen,Robert M. Kass,Jean R. Allard,C. Thomas Peter +5 more
TL;DR: The Medtronic PCD's onset and stability criteria reduced inappropriate detection of atrial fibrillation and sinus acceleration while detecting 99.5% of ventricular tachycardias.
Journal ArticleDOI
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.
Bruce L. Wilkoff,Laurent Fauchier,Martin K. Stiles,Carlos A. Morillo,Sana M. Al-Khatib,Jesœs Almendral,Luis Aguinaga,Ronald D. Berger,Alejandro Cuesta,James P. Daubert,Sergio J. Dubner,Kenneth A. Ellenbogen,N.A. Mark Estes,Guilherme Fenelon,Fermin C. Garcia,Maurizio Gasparini,David E. Haines,Jeff S. Healey,Jodie L. Hurtwitz,Roberto Keegan,Christof Kolb,Karl Heinz Kuck,Germanas Marinskis,Martino Martinelli,Mark A. McGuire,Luis G. Molina,Ken Okumura,Alessandro Proclemer,Andrea M. Russo,Jagmeet P. Singh,Charles D. Swerdlow,Wee Siong Teo,William Uribe,Sami Viskin,Chun Chieh Wang,Shu Zhang +35 more
TL;DR: This document systematically describes the >80% (83–100%, mean: 96%) required consensus achieved for each recommendation by official balloting in regard to the programming of (i) bradycardia mode and rate, (ii) tachycardia detection, (iii) tachedcardia therapy, and (iv) the intraprocedural testing of defibrillation efficacy.